SCHEMBL15467925

SCHEMBL15467925

Cc1ccc(C2(O)CCOc3cccnc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K14 Q99558 2/20 0.41
TRPM8 Q7Z2W7 1/20 0.34
OPRM1 P35372 2/20 0.33
OPRK1 P41145 2/20 0.33
OPRL1 P41146 2/20 0.33
ALDH1A1 P00352 3/20 0.33
GAA P10253 2/20 0.33
MAPT P10636 2/20 0.33
HSD17B10 Q99714 1/20 0.33
PDK2 Q15119 1/20 0.32
RAB9A P51151 1/20 0.32
AKT1 P31749 1/20 0.31
AKT2 P31751 1/20 0.31
SMN1; SMN2 Q16637 3/20 0.31
LMNA P02545 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
OPRD1 P41143 1/20 0.31
FGF23 Q9GZV9 1/20 0.30
CHRNA1 P02708 1/20 0.30
CHRNG P07510 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467914 0.88 MAP3K14 (0.49) MAP3K14TRPM8OPRM1OPRK1OPRL1
SCHEMBL15467441 0.87 MAP3K14 (0.49) MAP3K14TRPM8ALDH1A1GAAMAPT
SCHEMBL15468024 0.87 MAP3K14 (0.38) MAP3K14TRPM8CHRNA1CHRNGCHRNB1
SCHEMBL15469368 0.85 MAP3K14 (0.44) MAP3K14TRPM8OPRM1OPRK1OPRL1
SCHEMBL15467986 0.84 TRPM8 (0.37) MAP3K14TRPM8OPRM1OPRL1
SCHEMBL15467268 0.81 MAP3K14 (0.41) MAP3K14TRPM8RAB9ASMN1; SMN2CHRNA1
SCHEMBL15467465 0.81 TRPM8 (0.51) MAP3K14TRPM8SLC6A2SLC6A3
SCHEMBL15469390 0.80 AKT1 (0.33) TRPM8ALDH1A1GAAMAPTHSD17B10
SCHEMBL15469377 0.80 AKT1 (0.33) TRPM8ALDH1A1GAAMAPTHSD17B10
SCHEMBL15467483 0.78 MAP3K14 (0.39) MAP3K14TRPM8SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 MAP3K14 1097/4885TRPM8 1/4885OPRM1 184/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 MAP3K14 1097/4885TRPM8 1/4885OPRM1 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.